Stockscreener 앱 받기
59.97
0.25%
0.15
시간 외 거래:
60.07
0.10
+0.17%
전일 마감가:
$59.82
열려 있는:
$59.46
하루 거래량:
878.31K
Relative Volume:
1.99
시가총액:
$2.97B
수익:
$379.25M
순이익/손실:
$-77.34M
주가수익비율:
-37.20
EPS:
-1.6122
순현금흐름:
$-27.87M
1주 성능:
+15.28%
1개월 성능:
+19.30%
6개월 성능:
+17.45%
1년 성능:
+50.41%
1일 변동 폭
$57.79
$60.20
1주일 범위
$50.25
$61.00
52주 변동 폭
$36.86
$61.00
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
MIRM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
59.97 | 2.64B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-19 | 재개 | H.C. Wainwright | Buy |
| 2024-04-17 | 개시 | Stifel | Buy |
| 2023-12-18 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-13 | 개시 | Morgan Stanley | Overweight |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 재개 | Evercore ISI | Outperform |
| 2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2021-09-20 | 개시 | JP Morgan | Overweight |
| 2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-25 | 개시 | Robert W. Baird | Outperform |
| 2019-08-12 | 개시 | Citigroup | Buy |
| 2019-08-12 | 개시 | Evercore ISI | Outperform |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | ROTH Capital | Buy |
| 2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Mirum Pharmaceuticals Delivers Growth With Orphan Liver Drug Success - Finimize
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - MSN
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q2 2025 Earnings Call Transcript - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $89.00 at Evercore ISI - MarketBeat
Insider Selling at Mirum Pharmaceuticals: A Signal of Confidence or Caution for Long-Term Investors? - AInvest
HC Wainwright Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price - MarketBeat
BioLife Solutions: HC Wainwright Raises PT to $32, Maintains Buy Rating - AInvest
Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond James - TipRanks
Mirum Pharmaceuticals Reports Strong Q2 Growth and Raises Guidance - TipRanks
Mirum Pharmaceuticals Raises Revenue Guidance, Secures Reimbursement in Japan, and Expands Product Portfolio - AInvest
Citizens JMP Raises Mirum Pharmaceuticals Price Target to $81, Maintains Outperform Rating - AInvest
MIRM Stock Flying High: Too Late to Buy? - StocksToTrade
Mirum Pharmaceuticals shares rise 12.83% intraday after reporting strong Q2 results and raising 2025 guidance. - AInvest
MIRM Stock Up On Q2 Earnings And Revenue Beat, Raised 2025 View - Barchart.com
Mirum Soars 10.5% on Earnings Beat and Revenue Surge: A Biotech Breakout in the Making? - AInvest
Mirum Pharmaceuticals stock hits all-time high at 55.25 USD By Investing.com - Investing.com Australia
Mirum Pharmaceuticals stock hits all-time high at 55.25 USD - Investing.com
Mirum: JMP Securities Raises PT to $81, Maintains Market Outperform - AInvest
Mirum:Raymond James raises PT to $82, maintains Strong Buy rating. - AInvest
Mirum Pharmaceuticals stock price target raised to $80 from $73 at H.C. Wainwright - Investing.com Canada
Mirum:HC Wainwright Raises PT to $80, Maintains Buy Rating - AInvest
Mirum Pharmaceuticals stock price target raised to $81 by JMP - Investing.com South Africa
Mirum 2025 Q2 Earnings Losses Narrow Significantly - AInvest
Earnings call transcript: Mirum Pharmaceuticals sees revenue boost in Q2 2025 - Investing.com
Mirum Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Mirum Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Mirum Pharmaceuticals Q2 2025: Unpacking Contradictions on Market Penetration, Sales Growth, and Clinical Strategy - AInvest
Mirum Pharmaceuticals Reports Q2 2025 Earnings and Business Update - AInvest
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals soars as revenue crushes estimates - Investing.com
Mirum Pharmaceuticals earnings beat by $0.21, revenue topped estimates - Investing.com Canada
Mirum Pharmaceuticals reports Q2 EPS (12c), consensus (33c) - TipRanks
Earnings Flash (MIRM) Mirum Pharmaceuticals, Inc. Reports Q2 Revenue $127.8M, vs. FactSet Est of $108.1M - MarketScreener
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
Mirum Pharmaceuticals Q2 2025 Earnings Preview: EPS Estimate $-0.33, Revenue Estimate $108.1M. - AInvest
Traders Consider Averaging Down in Mirum Pharmaceuticals Inc.Community Verified Stock Suggestions Drive Volume - metal.it
Is Mirum Pharmaceuticals Inc. a growth stock or a value stockStay informed with expert market forecasts - Jammu Links News
How does Mirum Pharmaceuticals Inc. compare to its industry peersDiscover high-impact investment opportunities - Jammu Links News
What catalysts could drive Mirum Pharmaceuticals Inc. stock higher in 2025Unstoppable trading performance - Jammu Links News
Why is Mirum Pharmaceuticals Inc. stock attracting strong analyst attentionNavigate the market with precision tools - Jammu Links News
How many analysts rate Mirum Pharmaceuticals Inc. as a “Buy”Market-crushing profits - Jammu Links News
Should I hold or sell Mirum Pharmaceuticals Inc. stock in 2025Achieve rapid financial growth with smart picks - jammulinksnews.com
Is Mirum Pharmaceuticals Inc. stock overvalued or undervaluedRapid market gains - Jammu Links News
How does Mirum Pharmaceuticals Inc. generate profit in a changing economyMaximize returns with disciplined trading - Jammu Links News
How volatile is Mirum Pharmaceuticals Inc. stock compared to the marketHigh-profit trading signals - Jammu Links News
What analysts say about Mirum Pharmaceuticals Inc. stockUnmatched market performance - Jammu Links News
What are the latest earnings results for Mirum Pharmaceuticals Inc.Get ahead with breakthrough trading ideas - Jammu Links News
What makes Mirum Pharmaceuticals Inc. stock price move sharplyConsistently profitable trades - Jammu Links News
What are Mirum Pharmaceuticals Inc. company’s key revenue driversAchieve unparalleled market performance - Jammu Links News
Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - Lelezard
Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment - TipRanks
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):